Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DFLK16
|
|||
| Drug Name |
Sintilimab
|
|||
| Synonyms |
Tyvyt
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Hodgkin lymphoma [ICD-11: 2B30; ICD-10: C81, C81.9; ICD-9: 201] | Approved | [1] | |
| Company |
Innovent Biologics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death protein 1 (PD-1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Reactome | PD-1 signaling | |||
| WikiPathways | T-Cell Receptor and Co-stimulatory Signaling | |||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.